DACLIZUMAB for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 560 adverse event reports in the FDA FAERS database where DACLIZUMAB was used for Relapsing-remitting multiple sclerosis.
Most Reported Side Effects for DACLIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Alopecia | 450 | 16.1% | 0 | 21 |
| Transplant dysfunction | 421 | 15.0% | 3 | 8 |
| Transplant rejection | 385 | 13.8% | 3 | 8 |
| Acne | 382 | 13.6% | 0 | 4 |
| Ovarian cyst | 374 | 13.4% | 0 | 2 |
| Multiple sclerosis relapse | 313 | 11.2% | 6 | 230 |
| Drug ineffective | 229 | 8.2% | 19 | 28 |
| Pain | 224 | 8.0% | 1 | 20 |
| Pneumonia | 213 | 7.6% | 9 | 31 |
| Condition aggravated | 172 | 6.1% | 4 | 11 |
| Liver function test abnormal | 159 | 5.7% | 0 | 6 |
| Rheumatoid arthritis | 159 | 5.7% | 0 | 3 |
| Sleep disorder due to general medical condition, insomnia type | 146 | 5.2% | 0 | 2 |
| Fatigue | 134 | 4.8% | 0 | 36 |
| Memory impairment | 107 | 3.8% | 0 | 11 |
Other Indications for DACLIZUMAB
Multiple sclerosis (1,328)
Product used for unknown indication (441)
Transplant (143)
Prophylaxis against transplant rejection (98)
Immunosuppressant drug therapy (92)
Immunosuppression (60)
Renal transplant (50)
Graft versus host disease (15)
Birdshot chorioretinopathy (9)
Immunomodulatory therapy (6)
Other Drugs Used for Relapsing-remitting multiple sclerosis
OCRELIZUMAB (15,658)
FINGOLIMOD (8,814)
OFATUMUMAB (3,864)
DIMETHYL (3,638)
NATALIZUMAB (2,749)
INTERFERON BETA-1A (2,058)
GLATIRAMER (1,965)
ALEMTUZUMAB (1,604)
TERIFLUNOMIDE (1,320)
RITUXIMAB (956)